Campbell & CO Investment Adviser LLC Has $902,000 Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Campbell & CO Investment Adviser LLC grew its position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRMFree Report) by 90.7% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 28,556 shares of the company’s stock after purchasing an additional 13,582 shares during the quarter. Campbell & CO Investment Adviser LLC owned about 0.07% of Mirum Pharmaceuticals worth $902,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in MIRM. Raymond James Financial Services Advisors Inc. increased its stake in shares of Mirum Pharmaceuticals by 110.5% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 53,301 shares of the company’s stock valued at $1,174,000 after acquiring an additional 27,979 shares in the last quarter. Panagora Asset Management Inc. increased its stake in shares of Mirum Pharmaceuticals by 3.6% in the 1st quarter. Panagora Asset Management Inc. now owns 69,486 shares of the company’s stock valued at $1,530,000 after acquiring an additional 2,427 shares in the last quarter. BlackRock Inc. increased its stake in shares of Mirum Pharmaceuticals by 1.4% in the 1st quarter. BlackRock Inc. now owns 782,830 shares of the company’s stock valued at $17,238,000 after acquiring an additional 10,732 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 1st quarter valued at $440,000. Finally, Prudential Financial Inc. increased its stake in shares of Mirum Pharmaceuticals by 25.4% in the 1st quarter. Prudential Financial Inc. now owns 80,300 shares of the company’s stock valued at $1,768,000 after acquiring an additional 16,270 shares in the last quarter.

Mirum Pharmaceuticals Price Performance

MIRM opened at $27.98 on Friday. The company has a quick ratio of 4.91, a current ratio of 5.20 and a debt-to-equity ratio of 1.14. The firm’s fifty day moving average price is $29.02 and its two-hundred day moving average price is $28.78. Mirum Pharmaceuticals, Inc. has a 1 year low of $20.81 and a 1 year high of $35.56.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on MIRM shares. JMP Securities reiterated a “market outperform” rating and issued a $64.00 price objective on shares of Mirum Pharmaceuticals in a research note on Thursday, January 11th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $37.00 price target on shares of Mirum Pharmaceuticals in a research report on Monday, November 20th. Morgan Stanley began coverage on shares of Mirum Pharmaceuticals in a research report on Monday, November 13th. They issued an “overweight” rating and a $60.00 price target for the company. HC Wainwright reduced their price target on shares of Mirum Pharmaceuticals from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Monday, December 18th. Finally, Raymond James reduced their price target on shares of Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating for the company in a research report on Tuesday, December 19th. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $54.13.

Check Out Our Latest Stock Analysis on Mirum Pharmaceuticals

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 2,500 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, December 5th. The shares were sold at an average price of $32.40, for a total transaction of $81,000.00. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, insider Lara Longpre sold 1,019 shares of the business’s stock in a transaction dated Monday, January 8th. The shares were sold at an average price of $28.04, for a total value of $28,572.76. Following the transaction, the insider now directly owns 105,254 shares of the company’s stock, valued at approximately $2,951,322.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Jolanda Howe sold 2,500 shares of the business’s stock in a transaction dated Tuesday, December 5th. The stock was sold at an average price of $32.40, for a total transaction of $81,000.00. The disclosure for this sale can be found here. Insiders have sold 11,399 shares of company stock valued at $329,102 in the last three months. 24.06% of the stock is currently owned by insiders.

Mirum Pharmaceuticals Company Profile

(Free Report)

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.

See Also

Institutional Ownership by Quarter for Mirum Pharmaceuticals (NASDAQ:MIRM)

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.